Lenalidomid Teva

Lenalidomide, the active ingredient in Lenalidomid Teva, is an immunomodulatory imide drug (IMiD) presented as an oral formulation for oral use. It is employed in the treatment of certain blood cancers, including multiple myeloma, myelodysplastic syndromes with del(5q), and mantle‑cell lymphoma, typically in adult patients under specialist supervision.

GNH USA supplies Lenalidomid Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lenalidomid Teva is an immunomodulatory agent used in hematologic malignancies and related disorders. - Multiple myeloma: helps control disease progression and improve survival when used in combination regimens. - Myelodysplastic syndromes with del(5q): reduces transfusion dependence and may achieve cytogenetic remission. - Mantle cell lymphoma: contributes to disease control as part of approved therapeutic protocols.

Lenalidomid Teva may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced neutrophil count increasing infection risk. - Thrombocytopenia: lowered platelet levels leading to bleeding tendencies. - Fatigue: persistent tiredness affecting daily activities. - Nausea: upset stomach often occurring after dosing. - Constipation: difficulty passing stools. - Rash: mild skin irritation or erythema.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Secondary primary malignancies: emergence of new cancers. - Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances. - Severe allergic reactions: anaphylaxis or angioedema. - Hepatotoxicity: liver enzyme elevations indicating potential liver injury.

Before initiating therapy with Lenalidomid Teva, several safety considerations should be observed. - Monitor blood counts: perform regular CBC to detect cytopenias. - Assess renal function: adjust use in patients with impaired kidney clearance. - Avoid pregnancy: teratogenic risk requires strict contraception for both sexes. - Counsel on contraception: use effective methods throughout treatment and for a defined period after cessation. - Watch for thrombotic events: evaluate risk factors and consider prophylaxis when indicated. - Store at room temperature: keep in original packaging, protect from moisture and light.

Lenalidomid Teva can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase lenalidomide exposure. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic levels. - Live vaccines: risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin, DOACs): heightened bleeding risk. - NSAIDs: may exacerbate renal toxicity. - Other myelosuppressive agents: additive bone‑marrow suppression. - ACE inhibitors or ARBs: monitor renal function and electrolytes.